Project Grant W81XWH2210613

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $143,450 to support research on developing therapies for treating viral-induced acute lung injury. The primary focus is on evaluating the therapeutic efficacy of combinations of PPARG agonist and RXR ligand compounds in cotton rat models of influenza and respiratory syncytial virus (RSV) infection. The research...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $842,408 to Inspire RX LLC to develop and evaluate the Aerosolve Biohelmet. The Aerosolve Biohelmet is a personal negative pressure device designed to safely transport and treat patients with highly transmissible respiratory illnesses, including COVID-19, influenza, tuberculosis, and measles. The project aims to refine the Biohelmet...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Biotherapeutics, Inc. provides $347,608 to develop a novel, oral, once-daily immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) Characterize the therapeutic efficacy and route of administration of the drug candidate in mouse models of asthma, and 2) Determine the translational ability of the therapeutic candidate in human primary cells...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,000,000 to support the development of a novel nitric oxide-releasing formulation, ALX1, as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients. The key objectives are to: 1) enhance product quality and establish long-term stability of the ALX1 formulation; 2) identify optimal dosing regimens...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $185,509.00 to Texas A&M University System Health Science Center to conduct research on reducing lung immunopathology in a mouse model of mitochondrial disease. The key objectives are to: 1) Test the hypothesis that elevated type I interferon signaling and reduced NRF2 activity in POLG mutant macrophages promotes hyperinflammatory innate...

This $788,406 project grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases, under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund the development of a sensitive, direct reading bioaerosol detection platform to quantify airborne pathogens such as SARS-CoV-2. Aerosol Devices Inc. will integrate their gentle condensation-growth capture sampler, which concentrates intact, viable virus particles into a small liquid volume...

This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,193,262 to The Regents of the University of California, San Francisco to develop an adeno-associated virus-mediated SGPL1 gene therapy as a potential treatment for idiopathic pulmonary fibrosis (IPF). The research aims to confirm the efficacy of this gene therapy in reducing lung fibrosis and downstream profibrotic signaling, as well as optimize the therapy's...

This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $595,834 to Trellis Bioscience, Inc. to conduct a Phase 1 safety trial for TRL1068, an inhaled therapeutic monoclonal antibody targeting bacterial pneumonia. The award will support the development of TRL1068 as a novel treatment to disrupt bacterial biofilms and enhance the effectiveness of conventional...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $192,757 to the University of California, Davis to conduct research on the interaction between exposure to environmentally relevant hydrogen sulfide (H2S) concentrations and influenza A virus (IAV) infection. The key objectives of this 2-year study are to: 1) test the hypothesis that repeated exposure to H2S...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Parmedics, Inc., a for-profit, woman-owned biotechnology company, for the development of small molecule protease-activated receptor-2 (PAR2) antagonists as potential oral therapeutics for asthma. The goal is to characterize two novel PAR2 antagonists, C937 and C938, with improved pharmacodynamics and pharmacokinetics to enable...